Terminated PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT00967343

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

An Open-label, Uncontrolled, Multicenter, Multinational Study on the Efficacy and Safety of Administration of Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process, in Patients Receiving a CD34-selected Peripheral Blood Stem Cell Graft From a Related, Haploidentical Donor

Sponsor: Kiadis Pharma

Conditions Lymphoblastic Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndrome Myeloid Leukemia Myeloproliferative Disorders

Interventions Donor lymphocyte preparation depleted of host functional alloreactive T-cells

Updated 10 times since 2017 Last updated: May 19, 2021 Started: Aug 31, 2009 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Kiadis Pharma

Acute Lymphoblastic Leukemia · Phase PHASE3 · Dec 2021

More terminations from Kiadis Pharma

Listed as NCT00967343, this PHASE2/PHASE3 trial focuses on Lymphoblastic Leukemia and Lymphoma and remains terminated or withdrawn. Sponsored by Kiadis Pharma, it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Sep 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jun 2021 — Sep 2021 [monthly]

Terminated PHASE2_PHASE3

▶ Show 5 earlier versions

Feb 2021 — Jun 2021 [monthly]

Terminated PHASE2_PHASE3
Jan 2021 — Feb 2021 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2_PHASE3

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kiadis Pharma

Data source: Kiadis Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bruges, Belgium , Brussels, Belgium , Columbus, United States , Freiburg im Breisgau, Germany , Hamilton, Canada , Kiel, Germany , Leuven, Belgium , Liège, Belgium , London, United Kingdom , Maastricht, Netherlands and 5 more locations